New weekly pill aims to keep weight off after obesity treatment
NCT ID NCT07553299
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a weekly oral medication called ecnoglutide (VRB-101) to see if it can help people with obesity or overweight maintain their weight. Participants must have already been on weekly injections of semaglutide or tirzepatide for at least 6 months. The goal is to find the best dose for weight maintenance while monitoring safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Clinical Study Site 201
Little Rock, Arkansas, 72205, United States
-
Clinical Study Site 202
Cullman, Alabama, 35055, United States
-
Clinical Study Site 203
Phoenix, Arizona, 85028, United States
-
Clinical Study Site 204
Bradenton, Florida, 34209, United States
-
Clinical Study Site 205
Buffalo, New York, 14217, United States
-
Clinical Study Site 206
Lenoir, North Carolina, 28645, United States
-
Clinical Study Site 207
Richmond, Virginia, 23226, United States
-
Clinical Study Site 209
Jackson, Tennessee, 38305, United States
-
Clinical Study Site 210
Petal, Mississippi, 39465, United States
-
Clinical Study Site 211
Houston, Texas, 77040, United States
-
Clinical Study Site 212
Tempe, Arizona, 85281, United States
-
Clinical Study Site 213
El Dorado, Kansas, 67042, United States
-
Clinical Study Site 214
Santa Maria, California, 93454, United States
-
Clinical Study Site 215
St. Petersburg, Florida, 33704, United States
-
Clinical Study Site 216
Stamford, Connecticut, 06905, United States
-
Clinical Study Site 217
Houston, Texas, 77008, United States
-
Clinical Study Site 218
Irving, Texas, 75063, United States